Mithrl raised $20 million in a Series A led by Obvious Ventures to expand deployment of its biomedical world model across biopharma research teams. The company said it is building a second-generation platform intended to help R&D groups move from idea toward IND faster, positioning its AI as an agentic system routed over curated, validated biology rather than open-ended molecule generation. The platform, described as Mithrl-1, combines proprietary biomedical knowledge with agentic AI tools for model routing, token optimization, and content orchestration. Mithrl claims its approach runs with fewer compute tokens than standard workflows using frontier base models without customization, and that generated hypotheses include source citations and confidence scoring. The funding supports development and an early-access program for the next platform iteration, scheduled to open on September 21. For biopharma, the investment is part of an emerging push toward “reasoning over validated biology” to reduce time spent on downstream verification. If successful, Mithrl’s model architecture could complement internal translational pipelines by surfacing non-obvious links across disciplines while maintaining traceability to peer-reviewed sources.